© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
(Reuters) – The U.S. Food and Drug Administration said on Wednesday Eli Lilly (NYSE:) and Co’s COVID-19 drug bebtelovimab is not currently authorized for emergency use in the country as it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Be the first to comment